Skip to content

Effects and Cost-Effectiveness of rTMS on Upper Extremity Rehabilitation in Stroke Patients: a Multi-Center Randomized Controlled Trial

Effects and Cost-Effectiveness of rTMS on Upper Extremity Rehabilitation in Stroke Patients: a Multi-Center Randomized Controlled Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026842
Enrollment
Unknown
Registered
2019-10-24
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Experimental group:repetitive transcranial magnetic stimulation,rTMS
Control group:task-oriented training, TOT

Sponsors

The Second Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) first-ever stroke meeting the criteria of World Health Organization and the 5th national conference on cerebrovascular diseases in 2014, and confirmed by clinical neuroimaging (CT/MRI); (2) 1-12 months post stroke; (3) stable medical condition; (4) aged 18-85 years; (5) upper extremity motor impairment; (6) normal cardiopulmonary function, and stable vital signs; (7) commitment to follow the rules, and good cooperation in the study; (8) healthy lifestyle during the research; (9) some residual arm motor activity as defined by Brunnstrom recovery stages >= III; (10) able to provide informed consent.

Exclusion criteria

Exclusion criteria: (1) current consciousness disorders, psychosis, cognitive dysfunction, or mix aphasia limiting the ability to comply with evaluation and treatment regimen; (2) hypertonia with Ashworth scales >= III or manual muscle testing grade <= 2; (3) unstable cardiac, liver or renal diseases; (4) severe pain in the affected arm; (5) severe limitation of shoulder or elbow joint range of motion; (6) history of seizures; (7) severe orthopedic impairments in the affected arm; (8) unstable fracture or severe osteoporosis; (9) cardiac pacemaker or implanted device or metal in the brain; (10) severe disabilities prior to stroke (modified Rankin Scale, mRS = 5); (11) severe visual or auditory disorders; (12) pregnancy or lactation; (13) skull missing; (14) participation in concurrent clinical trial; (15) other diseases interferring with participants in the experiment.

Design outcomes

Primary

MeasureTime frame
Wolf Motor Function Test, WMFT;

Secondary

MeasureTime frame
the Upper Extremity Section of the Fugl-Meyer Assessment, FMA-UE;the Upper Extremity Section of the Modified Ashworth Scale, MASUE;Modified Barthe Index, MBI;Stroke-specific Quality of Life scale, SS-QOL;Motion Evoked Potential, MEP;

Countries

China

Contacts

Public ContactQiaojun Zhang

The Second Affiliated Hospital of Xi'an Jiaotong University

zhangqj@mail.xjtu.edu.cn+86 13891867155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026